ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

Paid and presented by Resmed. An eighth of the global population is affected by sleep apnoea, but this machine is helping improve the quality of life for those living with this obstructive disease.

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

ResMed's S7 Elite CPAP combines integrated humidification, data for both patients and clinicians, and a number of other features that produce optimal comfort, convenience, and patient involvement in ...

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

Both my parents use CPAP machines to treat their sleep apnea so ... but there are also bundles for ResMed AirSense 10 ($339), Fisher & Paykel ICON ($339), and others. The white sanitizing chamber ...

or CPAP, with another 34 million remaining undiagnosed. ResMed operates in over 140 countries with over 900 million people estimated to have sleep apnea globally, indicating the long runway for ...